Retinoic Acid, Its Receptors, and the Liver

视黄酸、其受体和肝脏

基本信息

  • 批准号:
    8465227
  • 负责人:
  • 金额:
    $ 32.32万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-06 至 2015-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Retinoids have broad effects including development, growth, cell death, and anti-oxidation. Their actions have been extensively studied in the skin, eye, and in many types of cancer. The liver is a major retinoic acid (RA) target site. Surprisingly, the action of RA in the liver has received very little attention. Our data generated in the past 10 years have uncovered many novel roles of retinoids in the liver. We showed that in the liver retinoids and their receptors have a broad spectrum of actions ranging from xenobiotic biotransformation to cholesterol, fatty acid, bile acid, carbohydrate, and amino acid homeostasis. In addition, hepatic retinoid signaling regulates cell proliferation and apoptosis as well as inflammation. Thus, we hypothesize that RA and its receptors regulate liver metabolism and function in general. The objective for the current application is twofold: to provide a hepatic genome-wide RA receptor target-gene profile in a gender-specific manner and to elucidate the mechanism by which RA and its receptors regulate gene transcription and expression. Among the diverse pathways, we propose to focus on studying the role of RA/receptors in regulating lipid homeostasis because hepatocyte RXR1 (retinoid x receptor 1) deficiency increases serum lipids and RA treatment reduces them in vivo. Furthermore, lack of hepatic RXR1 increases the susceptibility to develop steatosis and steatohepatitis. Three specific aims are proposed to study the global effect of RA/receptors in the liver and the underlying mechanisms. Aim 1 determines genome-wide RA/receptor target genes/pathways in the liver in a gender- specific manner using ChIP-sequencing and microarray analysis. The generated data may account for gender difference in liver function and susceptibility to liver disease. Aim 2 studies the mechanism by which retinoid- mediated pathways regulate lipid homeostasis. We propose to study the mechanisms that regulate two clusters of lipid homeostasis genes, which either do or do not respond to RA but both depend on hepatic RXR1 for their expressions. The transcriptional machinery, which dictates RA responsiveness, will be elucidated. Aim 3 studies the basal and RA-induced transcriptional machinery mediated by hepatic RXR1. We focus on PDK4, RAR2, and Cyp26a1 because our novel data show that these genes are induced by RA treatment as well as RXR1 deficiency. These genes have functional significance in either lipid homeostasis or RA efficacy. How retinoid signaling is controlled at the basal and RA-regulated level will be determined. The proposed study may be the first attempt to uncover the fundamental effects of retinoid signaling within the liver with an emphasis on lipid homeostasis. The generated data will have a huge impact on cancer, metabolic syndrome, diabetes, and cardiovascular disease as well as toxicology.
描述(由申请人提供):类视黄素具有广泛的影响,包括发育,生长,细胞死亡和抗氧化。他们的作用已在皮肤,眼睛和许多类型的癌症中进行了广泛的研究。肝脏是主要的视黄酸(RA)靶位点。令人惊讶的是,RA在肝脏中的作用很少受到关注。在过去的10年中,我们生成的数据已经发现了视视网膜类动物在肝脏中的许多新作用。我们表明,在肝类视网膜类似及其受体中,其作用范围很广,从异种生物生物转化到胆固醇,脂肪酸,胆汁酸,碳水化合物和氨基酸稳态。另外,肝类ot舌信号传导调节细胞增殖和凋亡以及炎症。因此,我们假设RA及其受体通常调节肝脏代谢和功能。当前应用的目的是双重的:以性别特异性的方式提供全肝基因组RA受体靶标谱,并阐明RA及其受体调节基因转录和表达的机制。在各种途径中,我们建议专注于研究RA/受体在调节脂质稳态中的作用,因为肝细胞RXR1(类视黄素X受体1)缺乏增加血清脂质并将RA治疗减少体内。此外,缺乏肝RXR1增加了发展脂肪变性和脂肪性肝炎的敏感性。提出了三个特定的目标来研究肝脏和潜在机制中RA/受体的全球效应。 AIM 1使用芯片序列和微阵列分析以性别特异性方式确定肝脏中全基因组RA/受体靶基因/途径。生成的数据可能解释了肝功能的性别差异和对肝病的易感性。 AIM 2研究了类维生素性介导的途径调节脂质稳态的机制。我们建议研究调节两个脂质稳态基因簇的机制,这些机制要么对RA做出反应或不反应RA,但两者都取决于肝RXR1的表达。指示RA响应能力的转录机械将被阐明。 AIM 3研究了由肝RXR1介导的基础和RA诱导的转录机械。我们专注于PDK4,RAR2和CYP26A1,因为我们的新数据表明这些基因是由RA处理以及RXR1缺乏诱导的。这些基因在脂质稳态或RA功效中具有功能显着性。将如何在基础和RA调节水平上控制类视黄素信号传导。拟议的研究可能是揭示肝脏内类视感信号传导的基本作用的首次尝试,重点是脂质稳态。生成的数据将对癌症,代谢综合征,糖尿病和心血管疾病以及毒理学产生巨大影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yu-Jui Yvonne Wan其他文献

Enrichment of nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors
视黄酸受体β介导的nur77富集导致芬维A胺和组蛋白脱乙酰酶抑制剂诱导人肝癌细胞凋亡
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    13.5
  • 作者:
    Hui Yang(杨辉);Qi Zhan;Yu-Jui Yvonne Wan
  • 通讯作者:
    Yu-Jui Yvonne Wan

Yu-Jui Yvonne Wan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yu-Jui Yvonne Wan', 18)}}的其他基金

Liver Cancer Therapy by MiR-22 and Its Inducers
MiR-22 及其诱导剂治疗肝癌
  • 批准号:
    10556373
  • 财政年份:
    2018
  • 资助金额:
    $ 32.32万
  • 项目类别:
Liver Cancer Therapy by MiR-22 and Its Inducers
MiR-22 及其诱导剂治疗肝癌
  • 批准号:
    10330455
  • 财政年份:
    2018
  • 资助金额:
    $ 32.32万
  • 项目类别:
Liver Cancer Therapy by MiR-22 and Its Inducers
MiR-22 及其诱导剂治疗肝癌
  • 批准号:
    10094055
  • 财政年份:
    2018
  • 资助金额:
    $ 32.32万
  • 项目类别:
Retinoic Acid, Its Receptors, and the Liver
视黄酸、其受体和肝脏
  • 批准号:
    8529067
  • 财政年份:
    2011
  • 资助金额:
    $ 32.32万
  • 项目类别:
COBRE: U OF KANSAS MEDICAL CTR: MOLECULAR BIOLOGY CORE
COBRE:堪萨斯大学医学 CTR:分子生物学核心
  • 批准号:
    8360780
  • 财政年份:
    2011
  • 资助金额:
    $ 32.32万
  • 项目类别:
Retinoic Acid, Its Receptors, and the Liver
视黄酸、其受体和肝脏
  • 批准号:
    8296548
  • 财政年份:
    2011
  • 资助金额:
    $ 32.32万
  • 项目类别:
Retinoic Acid, Its Receptors, and the Liver
视黄酸、其受体和肝脏
  • 批准号:
    8662762
  • 财政年份:
    2011
  • 资助金额:
    $ 32.32万
  • 项目类别:
Retinoic Acid, Its Receptors, and the Liver
视黄酸、其受体和肝脏
  • 批准号:
    8205418
  • 财政年份:
    2011
  • 资助金额:
    $ 32.32万
  • 项目类别:
COBRE: U OF KANSAS MEDICAL CTR: MOLECULAR BIOLOGY CORE
COBRE:堪萨斯大学医学 CTR:分子生物学核心
  • 批准号:
    8167659
  • 财政年份:
    2010
  • 资助金额:
    $ 32.32万
  • 项目类别:
Alcohol Pharmacogenetics in Mexican Americans
墨西哥裔美国人的酒精药物遗传学
  • 批准号:
    7854437
  • 财政年份:
    2009
  • 资助金额:
    $ 32.32万
  • 项目类别:

相似国自然基金

签字注册会计师动态配置问题研究:基于临阵换师视角
  • 批准号:
    72362023
  • 批准年份:
    2023
  • 资助金额:
    28 万元
  • 项目类别:
    地区科学基金项目
全生命周期视域的会计师事务所分所一体化治理与审计风险控制研究
  • 批准号:
    72372064
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
会计师事务所数字化能力构建:动机、经济后果及作用机制
  • 批准号:
    72372028
  • 批准年份:
    2023
  • 资助金额:
    42.00 万元
  • 项目类别:
    面上项目
会计师事务所薪酬激励机制:理论框架、激励效应检验与优化重构
  • 批准号:
    72362001
  • 批准年份:
    2023
  • 资助金额:
    28.00 万元
  • 项目类别:
    地区科学基金项目
环境治理目标下的公司财务、会计和审计行为研究
  • 批准号:
    72332002
  • 批准年份:
    2023
  • 资助金额:
    165.00 万元
  • 项目类别:
    重点项目

相似海外基金

Climate Change Effects on Pregnancy via a Traditional Food
气候变化通过传统食物对怀孕的影响
  • 批准号:
    10822202
  • 财政年份:
    2024
  • 资助金额:
    $ 32.32万
  • 项目类别:
The role of osteoblast progenitors in response to bone anabolic agents
成骨细胞祖细胞对骨合成代谢剂的反应的作用
  • 批准号:
    10404415
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
Determining medications associated with drug-induced pancreatic injury through novel pharmacoepidemiology techniques that assess causation
通过评估因果关系的新型药物流行病学技术确定与药物引起的胰腺损伤相关的药物
  • 批准号:
    10638247
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
PTSD and Autoimmune Disease: Towards Causal Effects, Risk Factors, and Mitigators
创伤后应激障碍 (PTSD) 和自身免疫性疾病:因果效应、危险因素和缓解措施
  • 批准号:
    10696671
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
Differences in Hospital Nursing Resources among Black-Serving Hospitals as a Driver of Patient Outcomes Disparities
黑人服务医院之间医院护理资源的差异是患者结果差异的驱动因素
  • 批准号:
    10633905
  • 财政年份:
    2023
  • 资助金额:
    $ 32.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了